About
RetInSight is a clinically validated, MDR-certified artificial intelligence platform designed to transform the management of retinal diseases through advanced OCT image analysis. Built on over a decade of academic research from the Medical University of Vienna and now part of Topcon Healthcare, RetInSight offers two flagship AI solutions for clinical routine: the GA Monitor and the Fluid Monitor. The GA Monitor revolutionizes the management of Geographic Atrophy (GA) by delivering accurate disease assessment and treatment evaluation directly from OCT scans, enabling clinicians to track progression with unprecedented precision. The Fluid Monitor targets neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO), providing quantitative fluid analysis and treatment response monitoring to reduce clinician workload and improve patient outcomes. RetInSight also supports clinical research organizations and pharmaceutical companies through AI-driven endpoints and biomarkers for clinical trials. The platform is flexible and integrates seamlessly as a stand-alone solution, through direct device integration, or via PACS integration, with cloud-based AI modules adaptable to diverse clinical workflows. Trusted by leading ophthalmologists across Europe and beyond, RetInSight reduces repetitive analytical tasks, increases efficiency, and enables earlier, more informed treatment decisions—ultimately helping to preserve patient eyesight throughout their lifetime.
Key Features
- GA Monitor: AI-driven tool for accurate assessment and longitudinal monitoring of Geographic Atrophy (GA) progression and treatment response from OCT images.
- Fluid Monitor: Automated fluid quantification for nAMD, DME, and RVO from OCT scans, enabling precise treatment response analysis and reducing manual workload.
- PACS & Device Integration: Flexible deployment options including cloud-based stand-alone, direct ophthalmic device integration, and PACS integration to fit existing clinical workflows.
- Clinical Study AI Solutions: Purpose-built AI modules for pharmaceutical and academic clinical trials, providing novel imaging biomarkers and endpoints for retinal disease research.
- MDR-Certified & Regulatory Approved: CE-marked under EU MDR with additional regulatory clearances in Australia (TGA) and New Zealand (Medsafe), ensuring clinical-grade safety and reliability.
Use Cases
- Ophthalmologists monitoring Geographic Atrophy progression in patients and evaluating the effectiveness of GA treatments using quantitative AI-driven assessments.
- Retinal specialists managing nAMD patients by tracking fluid levels over time with the Fluid Monitor to optimize anti-VEGF injection intervals.
- Eye care clinics integrating AI into daily workflows to reduce manual OCT reading time and improve diagnostic consistency across patient populations.
- Pharmaceutical companies using RetInSight's clinical study AI solutions to generate objective imaging biomarkers and endpoints for retinal disease drug trials.
- Academic medical institutions collaborating on retinal research by leveraging RetInSight's AI platform to derive novel insights from large OCT imaging datasets.
Pros
- Clinically Validated: Backed by over a decade of academic research from the Medical University of Vienna and validated in real-world clinical settings across Europe and beyond.
- Reduces Clinician Workload: Automates repetitive image analysis tasks, freeing ophthalmologists to focus more on patient care and treatment decisions.
- Regulatory Compliance: MDR-certified with approvals in multiple jurisdictions, making it suitable for use in regulated clinical and hospital environments.
- Flexible Integration: Supports stand-alone, device, and PACS integration, making it adaptable to a wide range of clinical IT infrastructures.
Cons
- Narrow Specialty Focus: The platform is specifically designed for ophthalmology and retinal disease, limiting its applicability outside of eye care.
- Enterprise Pricing: Tailored for clinical institutions and pharmaceutical companies; pricing and procurement are not transparent for smaller practices.
- Limited Public Documentation: Detailed technical specifications and integration guides are not publicly available and require direct contact with the vendor.
Frequently Asked Questions
What diseases does RetInSight support?
RetInSight supports monitoring and analysis of Geographic Atrophy (GA), neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) through OCT image analysis.
Is RetInSight certified for clinical use?
Yes. RetInSight is MDR-certified for use in the EU and has received regulatory approvals from Australia's TGA and Medsafe in New Zealand, qualifying it as a clinically validated medical device software.
How does RetInSight integrate into existing clinical workflows?
RetInSight offers three integration modes: stand-alone cloud-based access, direct integration with ophthalmic imaging devices, and PACS integration—allowing it to fit seamlessly into diverse hospital and clinic IT environments.
Can RetInSight be used in clinical trials?
Yes. RetInSight provides dedicated AI solutions for clinical studies, offering novel imaging biomarkers and quantitative endpoints for retinal disease research in pharmaceutical and academic trials.
Who developed RetInSight?
RetInSight was founded as a spin-off of the Medical University of Vienna and is built on over a decade of academic leadership in AI-based retinal image analysis. It was acquired by Topcon Healthcare in May 2025.
